## Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2024)	Global Fund ERP recommended	GDF Catalog
Ethambutol 400mg tablet/capsule											
Ethambutol/Isoniazid/Pyrazinamide/ Rifampicin 275/75/400/150mg tablet/ capsule											
Ethambutol/Isoniazid/Rifampicin 275/75/150mg tablet/capsule											
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Isoniazid/Rifampicin 75/150mg tablet/capsule											
Isoniazid/Rifampicin 150/300mg tablet/capsule											

DS-TB: Drug-Susceptible TB EML: Essential Medicines List **EOI:** Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2024







Status Yes No


N/A

Ineligible for inclusion



## Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



DS-TB: Drug-Susceptible TB EML: Essential Medicines List EOI: Expression of Interest **ERP**: Expert Review Panel

**SRA:** Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2024







Yes



## Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike** 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2024)	Global Fund ERP recommended	GDF Catalog	
Rifapentine 150mg tablet												
Rifapentine 300mg												
Rifapentine/Isoniazid 300mg/300mg tablet												
Rifapentine/Isoniazid/Moxifloxacin 300/75/100mg tablet												
Rifapentine/Isoniazid/Moxifloxacin/ Pyrazinamide 300/75/100/375mg tablet												

DS-TB: Drug-Susceptible TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2024







Status
Yes
No

N/A

Ineligible for inclusion

